Lobe Sciences (CSE: LOBE) CEO Philip Young tells Proactive he's looking forward to presenting at Proactive's One2One Virtual Investor Forum on February 23, at 1pm EST.
Young says he hopes investors understand how the group has made the transition to a fully-integrated psychedelics company from a cannabis company. He expects to expand upon the group's final closure of divesting its cannabis business.
Price: 0.17 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lobe Sciences Ltd named herein, including the promotion by the Company of Lobe Sciences Ltd in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS:GTSIF) CEO Philip Young presents at Proactive's One2One virtual investor forum. The Vancouver-based company is currently advancing unique medicines and devices to treat mild traumatic brain injury and post-traumatic stress disorder, as well as other...
Prev article
